A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Phase 3 Active not recruiting 90 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

Timeline

Start: 2022-12-30
Primary completion: 2026-02-20
Completion: 2028-12-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ianalumab	Monoclonal antibody	—	Intravenous

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Summary

Timeline

Drugs

Indications